SynthesisInternational journal of clinical oncology2026
Olaparib maintenance versus placebo or standard of care in ovarian cancer: a biomarker-driven systematic review and meta-analysis of randomized trials.
Synthesis in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOlaparib is widely used as maintenance therapy in advanced ovarian cancer following response to platinum-based chemotherapy, but the magnitude of benefit across molecular subgroups and its safety profile remain uncertain. This updated meta-analysis evaluated the efficacy and safety of olaparib maintenance therapy across biomarker-defined subgroups and treatment settings.
methodsPubMed, Embase, and the Cochrane Library were searched for randomized controlled trials. Two reviewers independently screened studies evaluating olaparib as maintenance therapy in patients with advanced ovarian cancer who achieved a response to platinum-based chemotherapy in either first-line or recurrent disease settings.
resultsPrimary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included time to first subsequent therapy (TFST), time to second subsequent therapy (TSST), and adverse events (AEs). Hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Eight randomized trials were included. Olaparib significantly improved PFS compared with control (HR 0.48; 95% CI 0.37-0.62; p < 0.01). The benefit was greater in BRCA-mutated patients (HR 0.33; 95% CI 0.22-0.52) than in BRCA wild-type patients (HR 0.62; 95% CI 0.47-0.82; p for interaction = 0.001). The largest benefit was observed in HRD-positive tumors (HR 0.44; 95% CI 0.35-0.54), whereas evidence of benefit in HRD-negative patients remained limited. OS showed a trend toward improvement overall (HR 0.82; 95% CI 0.66-1.02; p = 0.07) and was significantly improved among BRCA-mutated patients (HR 0.66; 95% CI 0.56-0.78). Olaparib also prolonged TFST and TSST but was associated with a higher risk of grade ≥ 3 AEs, without a statistically significant increase in hematologic adverse events.
conclusionOlaparib maintenance therapy significantly delays disease progression in advanced ovarian cancer, with the greatest benefit observed in BRCA-mutated and HRD-positive tumors. These findings support the role of olaparib maintenance therapy in biomarker-selected patients across first-line and recurrent treatment settings, while highlighting ongoing uncertainties in specific biomarker-defined subgroups.
Indexed as
Identifiers
42550402What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.